|Study Description:||The goal of the Phase I portion of this study is to find the highest tolerable |
dose of TPI 287 that can be given in combination with Temodar (temozolomide) to
patients with metastatic melanoma.
The goal of the Phase II portion of this study is to learn if TPI 287, given in
combination with temozolomide, can control metastatic melanoma. The safety of
this combination will also be studied.